Orbis Medicines
Frederiksberg
About Orbis Medicines
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery. Its platform delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. The company's pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $121.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2025)
- Website: orbismedicines.com
Industries & Categories
Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/orbis-medicines-25994 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.